Steven Rust

This inventor holds 9 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignee: Medimmune Limited. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven Rust. Retrieved from https://idiyas.com/inventor/steven-rust

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 7)

% Patents Active = 88.9

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 9.3

ph-index = 5

Forward Citations = 44(Granted Patents)

Company Filing History:

10 out of 546

Medimmune Limited

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

2. 11203633 - Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv (2021-12-21),

3. 11192948 - Compositions and methods for inhibiting cancer stem cells (2021-12-07),

4. 10844114 - Anti-Psl binding molecules and uses thereof (2020-11-24),

5. 10597439 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2020-03-24),

6. 10370436 - Anti-pseudomonas Psl binding molecules and uses thereof (2019-08-06),

7. 9884902 - CTLA-4 variants (2018-02-06),

8. 9580509 - Multispecific and multivalent binding proteins and uses thereof (2017-02-28),

9. 9403901 - Anti-pseudomonas Psl binding molecules and uses thereof (2016-08-02),

Title: The Innovative Contributions of Steven Rust

Introduction

Steven Rust is a prominent inventor based in Cambridge, GB, known for his significant contributions to the field of biotechnology. With a total of nine patents to his name, Rust has made remarkable strides in developing therapies aimed at combating infections caused by Pseudomonas aeruginosa.

Latest Patents

Among his latest patents, Rust has developed combination therapies using anti-Psl and PcrV binding molecules. This disclosure relates to therapies that comprise anti-Psl and PcrV binding molecules and related compositions, intended for the prevention and treatment of infections. Another notable patent involves polynucleotides encoding antibodies or antigen binding fragments that bind to PcrV, along with vectors and host cells that incorporate these polynucleotides.

Career Highlights

Rust is currently associated with Medimmune Limited, where he continues to innovate and contribute to the advancement of medical science. His work focuses on developing effective treatments for serious infections, showcasing his commitment to improving patient outcomes.

Collaborations

Throughout his career, Rust has collaborated with notable colleagues, including Ralph Raymond Minter and Antonio Digiandomenico. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Steven Rust's innovative work and dedication to biotechnology have led to significant advancements in infection treatment. His contributions continue to impact the medical field positively, demonstrating the importance of innovation in healthcare.

Profile summary based on public USPTO records.